Haemonetics Corporation (HAE)
NYSE: HAE · IEX Real-Time Price · USD
93.33
+1.20 (1.30%)
May 2, 2024, 4:00 PM EDT - Market closed

Haemonetics Revenue

Haemonetics had revenue of $1.27B in the twelve months ending December 30, 2023, with 12.48% growth year-over-year. Revenue in the quarter ending December 30, 2023 was $336.25M with 10.14% year-over-year growth. In the fiscal year ending April 1, 2023, Haemonetics had annual revenue of $1.17B with 17.67% growth.

Revenue (ttm)
$1.27B
Revenue Growth
+12.48%
P/S Ratio
3.73
Revenue / Employee
$418,649
Employees
3,034
Market Cap
4.74B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Apr 1, 20231.17B175.46M17.67%
Apr 2, 2022993.20M122.73M14.10%
Apr 3, 2021870.46M-118.02M-11.94%
Mar 28, 2020988.48M20.90M2.16%
Mar 30, 2019967.58M63.66M7.04%
Mar 31, 2018903.92M17.81M2.01%
Apr 1, 2017886.12M-22.72M-2.50%
Apr 2, 2016908.83M-1.54M-0.17%
Mar 28, 2015910.37M-28.14M-3.00%
Mar 29, 2014938.51M46.52M5.22%
Mar 30, 2013891.99M164.15M22.55%
Mar 31, 2012727.84M51.15M7.56%
Apr 2, 2011676.69M31.26M4.84%
Apr 3, 2010645.43M47.55M7.95%
Mar 28, 2009597.88M81.44M15.77%
Mar 29, 2008516.44M66.83M14.86%
Mar 31, 2007449.61M29.87M7.12%
Apr 1, 2006419.73M36.14M9.42%
Apr 2, 2005383.60M19.37M5.32%
Apr 3, 2004364.23M27.27M8.09%
Mar 29, 2003336.96M16.99M5.31%
Mar 30, 2002319.97M26.11M8.88%
Mar 31, 2001293.86M13.25M4.72%
Apr 1, 2000280.61M-3.90M-1.37%
Apr 3, 1999284.51M-1.25M-0.44%
Mar 28, 1998285.76M-17.25M-5.69%
Mar 29, 1997303.01M26.54M9.60%
Mar 30, 1996276.47M14.05M5.36%
Apr 1, 1995262.42M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Organon & Co. 6.26B
Bausch + Lomb 4.31B
Lantheus Holdings 1.30B
Halozyme Therapeutics 829.25M
Doximity 468.33M
CRISPR Therapeutics AG 371.21M
Glaukos 314.71M
Krystal Biotech 50.70M
Revenue Rankings